CLINICAL TRIALS PROFILE FOR LUMASON

All Clinical Trials for Lumason

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02282163 ↗	Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography	Terminated	Bracco Diagnostics, Inc	Phase 3	2015-10-01	Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.
NCT02522481 ↗	Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141	Completed	Bracco Diagnostics, Inc	Phase 3	2015-09-24	The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
NCT02552238 ↗	Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142	Completed	Bracco Diagnostics, Inc	Phase 3	2015-10-12	The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
NCT02911714 ↗	Contrast-Enhanced Ultrasound for Kidney Transplant	Recruiting	American Heart Association	Phase 1	2018-02-21	Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT02911714 ↗	Contrast-Enhanced Ultrasound for Kidney Transplant	Recruiting	National Kidney Foundation	Phase 1	2018-02-21	Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT02911714 ↗	Contrast-Enhanced Ultrasound for Kidney Transplant	Recruiting	Isaac E. Hall	Phase 1	2018-02-21	Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT03040323 ↗	Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses	Terminated	Indiana University	Phase 4	2016-12-22	The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.

Clinical Trial Conditions for Lumason

Condition Name

Condition Name for Lumason
Intervention	Trials
Hepatocellular Carcinoma	3
Abdominal Injury	2
Coronary Artery Disease	2
Glioma	1

Condition MeSH

Condition MeSH for Lumason
Intervention	Trials
Abdominal Injuries	4
Carcinoma	4
Carcinoma, Renal Cell	3
Wounds and Injuries	3

Clinical Trial Locations for Lumason

Trials by Country

Trials by Country for Lumason
Location	Trials
United States	60
Canada	2
United Kingdom	2
Italy	1
Germany	1

Trials by US State

Trials by US State for Lumason
Location	Trials
Pennsylvania	8
California	7
Missouri	5
Minnesota	5
Massachusetts	5

Clinical Trial Progress for Lumason

Clinical Trial Phase

Clinical Trial Phase for Lumason
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	2
PHASE1	2

Clinical Trial Status

Clinical Trial Status for Lumason
Clinical Trial Phase	Trials
Recruiting	15
NOT_YET_RECRUITING	4
Completed	4

Clinical Trial Sponsors for Lumason

Sponsor Name

Sponsor Name for Lumason
Sponsor	Trials
Bracco Diagnostics, Inc	5
Mayo Clinic	5
National Cancer Institute (NCI)	4

Sponsor Type

Sponsor Type for Lumason
Sponsor	Trials
Other	40
Industry	9
NIH	6

Lumason (Sulfur Hexafluoride Lipid Nanoemulsion): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 30, 2025

Introduction

Lumason (sulfur hexafluoride lipid nanodroplets) is an ultrasound contrast agent developed for enhancing diagnostic imaging, particularly in echocardiography and hepatic imaging. Since its FDA approval in 2014, Lumason has established a niche in the medical imaging arena, providing clinicians with enriched visualization of blood flow and tissue vascularity. This report offers an in-depth update on ongoing clinical trials, a comprehensive market analysis, and future projections that illuminate Lumason’s trajectory in the global diagnostics market.

Clinical Trials Update

Regulatory Status and Ongoing Research

Lumason, known commercially as SonoVue outside the United States, received FDA approval in 2014 for intravenous use in echocardiography and hepatic imaging. Post-approval, the product has mostly been utilized in routine clinical practice, with limited formal clinical trials explicitly aimed at expanding its indications within the U.S.

However, ongoing investigations globally aim to explore its utility across various diagnostic applications:

• Expanding Indications: Several investigator-initiated trials are assessing Lumason's effectiveness in pediatric populations, where contrast-enhanced ultrasound (CEUS) could reduce reliance on more invasive or radiation-intensive techniques such as CT or MRI [1].

• Cancer Detection and Characterization: Studies in Europe and Asia are evaluating Lumason’s role in detecting liver metastases, hepatocellular carcinoma (HCC), and characterizing indeterminate hepatic lesions. Early results indicate high sensitivity and specificity, comparable or superior to traditional imaging modalities [2].

• Guidance for Therapeutic Interventions: Trials are underway to examine the efficacy of Lumason in guiding biopsies and minimally invasive procedures, especially in challenging anatomical regions [3].

Noteworthy Trial Highlights and Future Prospects

While large-scale, phase III trials are scarce within the U.S., the global research community continues to explore CEUS-based applications, which could indirectly influence Lumason’s utilization and regulatory approval for new indications. The European Medicines Agency (EMA) continues to support CEUS applications, with ongoing studies required to broaden Lumason’s label in the EU.

Safety Profile and Regulatory Considerations

The safety profile of Lumason remains favorable — adverse events are rare and generally mild. Nonetheless, post-market surveillance and real-world data collection are ongoing, aiming to identify any infrequent adverse reactions that could influence future indications or labeling updates.

Market Analysis

Market Overview

Lumason’s primary market comprises healthcare providers requiring advanced ultrasound contrast agents for diagnostic clarity. The global ultrasound contrast agent market was valued at approximately USD 1.2 billion in 2022 and is projected to expand at a CAGR of over 7% through 2030 [4].

Within this landscape, Lumason holds approximately 40-45% of the US contrast agent market segment, with notable competition from agents like Definity (Luminity outside the U.S.) and SonoVue (Europe).

Key Market Drivers

• Expanding Adoption of CEUS: Increasing awareness among radiologists and cardiologists about CEUS benefits, including its safety in renal impairment and pregnant women, fuels growth.
• Cost-Effectiveness: CEUS with Lumason often reduces reliance on expensive CT and MRI scans, encouraging insurance reimbursement and hospital adoption.
• Regulatory Approvals Outside the U.S.: Broader regulatory coverage enhances global footprint, especially in Europe, Asia, and Latin America.

Challenges and Limitations

• Limited Indication Expansion: Regulatory constraints restrict Lumason primarily to cardiac and hepatic imaging within the U.S., limiting potential revenue from broader applications.
• Competitive Landscape: Biotech firms developing novel contrast agents and alternative imaging modalities pose perpetual competition.

Market Segmentation and Geographic Breakdown

• United States: Dominates fast adoption owing to regulatory approval and widespread clinical familiarity.
• Europe: The main growth driver outside the U.S., propelled by the EMA’s approval for CEUS in liver imaging and ongoing clinical trials.
• Asia-Pacific: Rapidly expanding due to increasing healthcare infrastructure investment, particularly in China and Japan.

Revenue Trends

From 2014 through 2022, Lumason’s sales have exhibited consistent growth, with annual revenues approaching USD 100 million by 2022. Future projections suggest a compound annual growth rate (CAGR) of approximately 8-10%, driven by expanded indications and increasing global penetration.

Future Projections

Growth Opportunities

• Indication Expansion: Regulatory approval for new indications such as pediatric imaging, oncology, and vascular assessments could significantly increase market size.
• Global Expansion: Penetration into emerging markets with growing diagnostic imaging needs offers additional upside.
• Technological Integration: Integration with advanced ultrasound systems utilizing artificial intelligence (AI) for enhanced image interpretation could boost adoption rates.

Potential Barriers

• Regulatory Rigidity: Stringent approval processes and delays in indication expansion may slow growth.
• Market Penetration: Entrenched competition and limited awareness in certain regions can impede market share gains.
• Pricing and Reimbursement Dynamics: Varying reimbursement policies across countries may influence sales trajectories.

Forecast Summary

By 2030, Lumason’s global sales are forecasted to reach approximately USD 250-300 million, supported by broader approvals, technological integration, and increasing clinician adoption of CEUS as a first-line imaging modality.

Key Takeaways

• Clinical Research Continues to Evolve: While Lumason’s primary indications remain well-established, ongoing trials in oncology and pediatric imaging could open new revenue streams.
• Market Expansion Driven by Regulatory Approvals: Broader approval outside the U.S. in Europe and Asia is crucial for sustained growth.
• Competitive Landscape Remains Intense: Differentiation through clinical evidence and regulatory hurdles will shape Lumason’s market share.
• Technological Synergies Present Opportunities: Integration with AI and advanced ultrasound platforms may accelerate adoption.
• Long-term Growth Prospects Are Promising: With strategic expansion and indication approval, Lumason is well-positioned to capitalize on the expanding global ultrasound contrast agent market.

FAQs

1. What are the main clinical applications of Lumason?
Lumason is primarily used in echocardiography for improved visualization of cardiac chamber structures and blood flow, and in hepatic imaging for lesion characterization and detection of liver pathology.

2. Are there ongoing trials to expand Lumason’s indications?
Yes. Several international studies aim to evaluate Lumason’s efficacy in pediatric populations, oncology imaging, and guiding minimally invasive procedures.

3. How does Lumason compare with other ultrasound contrast agents?
Lumason offers a favorable safety profile and excellent imaging enhancement. Its adoption depends on regional approvals, clinician familiarity, and reimbursement policies.

4. What are the key growth factors for Lumason in the coming years?
Indication expansion, global regulatory approvals, increasing use of CEUS, and technological advancements in ultrasound imaging are primary growth drivers.

5. How might regulatory delays impact Lumason’s market potential?
Delays in approval for new indications or regions could restrict growth opportunities, emphasizing the importance of ongoing clinical evidence and strategic regulatory engagement.

References

1. European Society of Radiology. (2022). CEUS in Pediatric Imaging: Current Status and Future Perspectives.
2. Liver International. (2021). Diagnostic Accuracy of CEUS with Lumason in Hepatic Lesions.
3. Society of Interventional Radiology. (2020). Imaging-guided Interventions using Contrast Agents.
4. MarketsandMarkets. (2022). Ultrasound Contrast Agents Market Report.